You're signed outSign in or to get full access.
SR One Capital Management, LP
SR One Capital Management, LP is a biotechnology-focused venture capital firm headquartered in Wayne, Pennsylvania, with additional offices in San Francisco, CA and London, UK. Originally founded as the corporate venture capital arm of GlaxoSmithKline in 2003, it now operates independently. The firm specializes in early-stage and growth investments in life sciences, particularly in therapeutics, medical devices, and healthcare services. SR One supports its portfolio with both financial investment and strategic guidance, aiming to transform cutting-edge scientific research into impactful medicines for patients with significant unmet needs. The firm employs approximately 24 to 42 people, depending on the source, and maintains a transatlantic reach in key biotech hubs.
Investment Strategy
SR One takes a back-and-build approach to venture investing, focusing on companies with strong underlying science and a clear path to development. Its strategy prioritizes asset-centric, innovation-driven biotechnology companies with the potential to address diseases from new scientific perspectives. The team partners closely with entrepreneurs and scientists to foster next-generation therapies, providing both capital and operational expertise to accelerate growth and advance medical innovation. SR One typically invests in early-stage and select later-stage private biotech companies, with a thematic focus on novel targets and platforms with high transformative potential.
Latest 13F Filing Activity
SR One Capital Management, LP filed their most recent 13F report on Jun 30, 2025 disclosing 12 equity positions with a total 13F market value of $461M. The fund increased holdings in Oric Pharmaceuticals, Inc., Ars Pharmaceuticals, Inc., Crispr Therapeutics AG among other positions. SR One Capital Management, LP reduced exposure to Mineralys Therapeutics Inc., Alumis Inc., Design Therapeutics, Inc. among others.
Top Holdings
Equity Positions (12)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
A ACLX | Arcellx, Inc. | 33.49% | $154.5M | 2,346,630 | $14.02 | $65.85 | +$586.7K |
S SPRY | ARS Pharmaceuticals, Inc. | 15.18% | $70.0M | 4,012,903 | $8.02 | $17.45 | +$19.5M |
C CRSP | CRISPR Therapeutics AG | 11.06% | $51.0M | 1,048,951 | $68.18 | $48.64 | +$15.3M |
Z ZBIO | Zenas BioPharma, Inc | 10.32% | $47.6M | 4,911,539 | $16.92 | $9.69 | +$8.8M |
O ORIC | ORIC Pharmaceuticals, Inc. | 9.93% | $45.8M | 4,514,929 | $10.15 | $10.15 | +$45.8M |
Industry Allocation
Investment Team (4)
| Name | Role | Location | |
|---|---|---|---|
J Jake Nunn | Partner | Los Altos, CA , United States | |
 | Partner | San Mateo, CA , United States | |
K Katarina Pance | Investment Professional | United States | |
R Rajeev Dadoo | Managing Partner | CA , United States |
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more